BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17525890)

  • 1. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia.
    Tallman MS; Abutalib SA; Altman JK
    Semin Thromb Hemost; 2007 Jun; 33(4):330-8. PubMed ID: 17525890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment concepts of acute promyelocytic leukemia.
    Lengfelder E; Saussele S; Weisser A; Büchner T; Hehlmann R
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):261-74. PubMed ID: 16236522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute promyelocytic leukemia: recent advances in diagnosis and management.
    Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
    Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemostatic problems in acute promyelocytic leukaemia.
    Arbuthnot C; Wilde JT
    Blood Rev; 2006 Nov; 20(6):289-97. PubMed ID: 16757074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open issues on bleeding and thrombosis in acute promyelocytic leukemia.
    Sanz MA; Montesinos P
    Thromb Res; 2010 Apr; 125 Suppl 2():S51-4. PubMed ID: 20434005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombosis during all-trans-retinoic acid therapy in a child with acute promyelocytic leukemia and factor VQ 506 mutation.
    Koçak U; Gürsel T; Oztürk G; Kantarci S
    Pediatr Hematol Oncol; 2000 Mar; 17(2):177-80. PubMed ID: 10734661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curative therapeutic approaches to APL.
    Tallmann MS
    Ann Hematol; 2004; 83 Suppl 1():S81-2. PubMed ID: 15124685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical roundtable monograph. Early death in patients with acute promyelocytic leukemia.
    Tallman M; Lo-Coco F; Kwaan H; Sanz M; Gore S
    Clin Adv Hematol Oncol; 2011 Feb; 9(2):1-16. PubMed ID: 22379665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravascular clotting activation and bleeding in patients with hematologic malignancies.
    Tallman MS; Kwaan HC
    Rev Clin Exp Hematol; 2004 Jun; 8(1):E1. PubMed ID: 16029967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed disease.
    Sirulnik LA; Stone RM
    Clin Adv Hematol Oncol; 2005 May; 3(5):391-7, 429. PubMed ID: 16167012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of anthracycline-based combination chemotherapy with or without all-trans retinoic acid in acute promyelocytic leukemia.
    Raza S; Ullah K; Ahmed P; Khan B
    J Coll Physicians Surg Pak; 2008 Sep; 18(9):546-50. PubMed ID: 18803891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate.
    Ohno R; Asou N; Ohnishi K
    Leukemia; 2003 Aug; 17(8):1454-63. PubMed ID: 12886231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding and thrombosis in acute promyelocytic leukemia.
    Choudhry A; DeLoughery TG
    Am J Hematol; 2012 Jun; 87(6):596-603. PubMed ID: 22549696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome.
    Yanada M; Matsushita T; Asou N; Kishimoto Y; Tsuzuki M; Maeda Y; Horikawa K; Okada M; Ohtake S; Yagasaki F; Matsumoto T; Kimura Y; Shinagawa K; Iwanaga M; Miyazaki Y; Ohno R; Naoe T
    Eur J Haematol; 2007 Mar; 78(3):213-9. PubMed ID: 17241371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia.
    Rodeghiero F; Castaman G
    Leukemia; 1994; 8 Suppl 2():S20-6. PubMed ID: 7815832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients.
    Dally N; Hoffman R; Haddad N; Sarig G; Rowe JM; Brenner B
    Thromb Res; 2005; 116(2):109-14. PubMed ID: 15907524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Leukemogenesis and therapy of acute promyelocytic leukemia: from the worse to the most favorable subtype of acute myeloid leukemia].
    Korístek Z; Mayer J
    Vnitr Lek; 2008; 54(7-8):701-27. PubMed ID: 18780571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia.
    Ventura GJ; Hester JP; Dixon DO; Khorana S; Keating MJ
    Hematol Pathol; 1989; 3(1):23-8. PubMed ID: 2745357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The coagulopathy of acute promyelocytic leukaemia revisited.
    Stein E; McMahon B; Kwaan H; Altman JK; Frankfurt O; Tallman MS
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):153-63. PubMed ID: 19285282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.